Zeiss Medical Technology has received China’s National Medical Products Administration (NMPA) approval for its retinal imaging device, CLARUS 700.
The CLARUS 700 is designed as a comprehensive ultra-widefield retinal camera, enabling eye care specialists to capture images in true colour with superior quality.
The device includes a complete suite of modalities, such as fluorescein angiography, which is crucial for assessing nonperfused retinal areas.
The imaging system captures images that closely resemble the natural colouration of the fundus as seen during direct clinical observation.
When used together with its patented technology and algorithms, the system would maximise workflow efficiency and reduce chair time for patients, said Zeiss .
Zeiss Medical Technology chronic disease management head Anuj Kalra said: “Zeiss CLARUS 700 represents a major step forward in retinal imaging.
“By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-colour reproduction, this system delivers unprecedented clarity for comprehensive visualisation from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the Zeiss Retina Workflow.”
The CLARUS 700 offers advanced features, such as PrecisionFocus, QuickCompare, and AutoBright, which assist ophthalmologists in diagnosing and monitoring retinal diseases.
The device captures 133° in a single image and up to 267° with multiple captures, providing detailed views of the retina.
Also, it is equipped with both fluorescein angiography and live infrared imaging capabilities.
The approval allows the company to provide ophthalmologists in China with advanced retinal diagnostic capabilities with ultra-widefield, high-resolution imaging.
Furthermore, the Zeiss Imaging Spotlight showcases unique and challenging fundus imaging cases, providing diagnostic insights into various pathologies.
Zeiss Medical Technology China sales and services head Maxwell Liu said: “Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks.
“It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients.”
In April this year, Zeiss secured the US Food and Drug Administration (FDA) 510(k) approval for its advanced robotic-assisted system, the Intrabeam 700 platform.
Intrabeam 700 provides precision to enhance intraoperative radiation therapy (IORT).
Its digital-first architecture facilitates Smart workflow efficiency and seamless connectivity, benefiting patients with neuro-oncology and breast cancer.
